Advances in the treatment of patients with pancreatic cancer: Improvement in symptoms and survival time

British Journal of Cancer

Volumn 78, Issue SUPPL. 1, 1998, Pages 9-13

  Von Hoff, D D ^a,b   Goodwin, A L ^a   Garcia, L ^a  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Capecitabine; Clinical benefit; Gemcitabine; MTA; Pancreatic cancer; Survival

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; PEMETREXED; PROTEIN P53;

ADENOVIRUS; ALOPECIA; ANEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PAIN; PANCREAS CANCER; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; THROMBOCYTOPENIA; TUMOR GROWTH; VIRUS REPLICATION; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DEOXYCYTIDINE; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 0031855524     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.748     Document Type: Article

References (37)

1. Andersen JS, Burris HA, Casper E, Clayman M, Green M, Nelson RL, Portenoy R, Rothenberg M, Tarassoff PG and Von Hoff DD (1994) Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 13: 461
2. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RC, Neoptolemos J and Williamson RC (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64: 1076-1082
3. Black RJ, Bray F, Ferlay J and Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33: 1075-1107
4. Brown T, O'Rourke T, Burris H, Kuhn J, Tarasoff P, Cagnola J, Rodriguez G and Von Hoff D (1991) A phase I trial of gemcitabine (LY188011) administered intravenously every two weeks. Proc Am Soc Clin Oncol 10: 115
5. Bukowski RM, Balcerzak SP, O'Bryan RM, Bonnet J and Chen T (1983) Randomized trial of FUra and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Cancer 52: 1577-1582
6. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarrassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413
7. Carmichael J, Fink U, Russell RC, Spittle MF, Harris B, Spiessel G and Blatter J (1995) Phase II study of gemcitabine in patient with advanced pancreatic cancer. Br J Cancer 73: 101-105
8. Casper ES (1993) Pancreatic cancer: how can we progress? Eur J Cancer 29A (suppl. 2): 171-172
9. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B and Tarrassoff PG (1994) Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34
10. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE and Everson LK (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061-2067
11. Cullinan S, Moertel CG, Wieand HS, Schott AI, Krook JE and Foley IF (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65 (suppl. 10): 2207-2212
12. Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffen T, Osterwalder B, Dalley D, Padzur R and Verweij J (1997) A randomised phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16: 227, A798
13. Fishman B, Pasternak S and Wallenstein SL (1987) The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 60: 1151-1158
14. Frey C, Twomey P, Keehn R, Elliott D and Higgins G (1981) Randomized study of 5FU and CCNU in pancreatic cancer. Cancer 47: 27-31
15. Ganly I, Kirn D, Rodriguez GI, Soutar D, Eckhardt G, Otto R, Robertson AG, Park O, Gulley ML, Kraynak M, Heise C, Maack C, Trown PW, Kaye S and Von Hoff DD (1997) Phase I trial of intratumoural injection with an E1B-attenuated adenovirus, ONYX-015, in patients with recurrent p53(-) head and neck cancer. Proc Am Soc Clin Oncol 16: 382
16. Gelber RD (1996) Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann Oncol 7: 335-337
17. Ghandi V and Plunkett W (1990) Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50: 3675-3680
18. GITSG (1986) Phase II studies of drug combinations in advanced pancreatic carcinoma. J Clin Oncol 4: 1794-1799
19. Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB and Von Hoff DD (1992) Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony-forming units. Anti-Cancer Drugs 3: 143-146
20. Heinemann V, Hertel L, Grindey GB and Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosyl cytosine. Cancer Res 48: 4024-4031
21. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD and Kirn DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 3: 639-645
22. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd CG and Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422
23. Horton J, Gelber R, Engstrom P, Falkson G, Moertel C and Brodovsky H (1981) Trials of single agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treat Rep 65: 65-67
24. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117
25. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E and Bocet J (1991) A phase III comparison trial of streptozotocin, mitomycin and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68 (suppl. 5): 965-969
26. Moore MJ (1994) Current status of chemotherapy in advanced pancreatic cancer. Curr Oncol 1: 212-216
27. O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee PG, Tarassoff F and Von Hoff DD (1994) Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30A: 417-418
28. Oster MW, Gray R, Panasci L and Perry MC (1986) Chemotherapy for advanced pancreatic cancer. A comparison of FAM with FSM. Cancer 57: 29-34
29. Parker SL, Tong T, Bolden S and Kringo PA (1997) Cancer statistics 1997. CA: A Cancer Journal for Clinicians 47: 3-27
30. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, Clark G, Faries D, Lu P and Von Hoff DD (1995) Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13: 2842-2850
31. Rinaldi DA, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Fields SM, Woodworth JR, Kuhn JG, Langley C, Clark G, Lu P and Von Hoff DD (1996) A phase I evaluation of LY231514, a novel multi-targeted antifolate administered every 21 days. Proc Am Soc Clin Oncol 15: 489
32. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Ponenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Stomiolo A-M and Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann Oncol 7: 347-353
33. Taylor I (1993) Should further studies be carried out in pancreatic cancer? Eur J Cancer 29A (suppl. 8): 1076-1078
34. Twelves C, Budman DR, Creaven PJ, Schellens JHM, Kuroma I, Dumont E, Osterwalder B and Reigner BG (1996) Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 15: 476
35. Von Hoff DD and the San Antonio Drug Development Team (1996) Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. Invest New Drugs 14: 265-270
36. Wick M, Mangold G, Dexter D, Perkins W, Eckhardt G and Von Hoff D (1997) Combination drug study with sodium phenyl acetate and gemcitabine against the MIAPaCa human pancreatic cancer xenograft. Proc Am Assoc Cancer Res 38: 87-88
37. Wils JA (1991) Chemotherapy in pancreatic cancer: a rational pursuit (review). Anti-Cancer Drugs 2(suppl. 1): 3-10